Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: insulin degludec/insulin aspartDrug: biphasic insulin aspart 30
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 447
- Registration Number
- NCT01009580
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kocaeli, Turkey
A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01006057
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 687
- Registration Number
- NCT01006291
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 28
- Registration Number
- NCT01002768
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Drug: placeboDrug: liraglutide
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT00993304
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Aarhus C, Denmark
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00992537
Investigation of the Response Relationship of NN5401 in Type 1 Diabetics
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- Interventions
- Drug: insulin degludec/insulin aspartDrug: biphasic insulin aspart 30
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00993096
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Phase 3
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A
- Interventions
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 214
- Registration Number
- NCT00984126
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Safety and Tolerability of NN9068 in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00983021
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-09-23
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1030
- Registration Number
- NCT00982644
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Valencia, Spain
© Copyright 2025. All Rights Reserved by MedPath